# An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy

> **NCT02907619** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 59 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** PF-06252616

## Key facts

- **NCT ID:** NCT02907619
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-13
- **Primary completion:** 2018-11-22
- **Final completion:** 2018-11-22
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Termination Date: 30Aug2018; Reason for termination: Lack of Efficacy
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907619, "An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02907619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*